Efficacy and safety of Covid-19 treatments - a summary of the methodology and results

Please join us on Wednesday 30th March, 14.00 - 15.00 (GMT) to hear Névine Zariffa, ICODA's Driver Project 1 Lead & President of the NMD Group, and Jaap Mandema (Chief Innovation Officer, Certara), talk about the work their team has carried out over the last 18 months to conduct a holistic evaluation of the efficacy and safety of treatments of COVID-19. In the presentation we will hear about repurposed drugs that were studied in both randomized clinical trials and observational real-world studies.  The team systematically evaluated both types of studies to see if their results aligned or diverged, and what factors might explain the divergence if any.  They also evaluate whether an initial methodology for combining both sets of studies can provide us reliable and faster answers about the therapeutic potential of repurposed drugs to treat COVID19.  This is an exciting opportunity to hear the results of this important body of work. 



Connecting Excellence in Data Science across Africa

14/12/21 Side session at the CPHIA2021 conference

Chaired by Dr Thomas Nyrienda, EDCTP & Faith Nfii, AfricaCDC

Talk 1 - Prof Nicky Moulder eLwazi Open Data Science Platform and Coordinating Center
Talk 2 - Dr Mahamoud Sama Cherif Maximising health gains from existing data: experience from Ebola
Talk 3 - Sammy Khagayi, Data Analyst, KEMRI- CGHR, East Africa Consortium for Clinical research (EACCR)
Talk 4 - Lauren Hookham IROC study, Uganda Incidence and risk factors for COVID-19 among pregnant and lactating women and their infants in Uganda
Talk 5 - Hannah Hussey, Jamy-Lee Bam, Alex Heekes ACCORD study, South Africa The Western Cape Provincial Health Data Centre model, and experience with SARS-CoV-2
Talk 6 - Naomi Waithira Reuse of clinical research data: from barriers to opportunities.


View this webinar in full screen


Evaluating the Global Impact of COVID-19 on Child Health and Births


In 2018 at least 5.3 million children under 5 years died globally of preventable conditions which include. While gains have been made over the years to improve access to New-born and Child health services in low-and- middle income countries, some gaps still exist. It is therefore imperative that the global community assesses the impact of COVID-19 on new born and child health using high quality data, and to understand the underlying cause(s) to ensure that the hard-won gains from many years of investments are not eroded in the short term.

Talk 1 - Studying Perinatal Health Internationally during the COVID-19 Pandemic: The iPOP Study.
Talk 2- Repercussions of social isolation due to Covid19 on Neonatal ICU child patients.


View this webinar in full screen

Equitably Harnessing the Power of Health Data: Time for Action and Collaboration


The COVID-19 pandemic has highlighted the critical importance of generating rigorous evidence for decision-making. To bring equity, the global health research community needs to find ways to unite and generate actionable insights from data. This interactive session will explore how collaborations and strategic partnerships can harness the power of data to tackle the most devastating health issues. We will draw on the experience of The Global Health Network and the International COVID-19 Data Alliance, convened by Health Data Research UK, and several speakers from around the world.


View the event in fullscreen